Aggressive Non-Hodgkin Lymphoma
Associated Genetic Biomarkers
NCI Definition: A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and angioimmunoblastic T-cell lymphoma. 
Aggressive non-hodgkin lymphomas most frequently harbor alterations in TET2, ATM, TP53, DNMT3A, and IDH2 .
TET2 Mutation, TET2 Frameshift, ATM Mutation, TP53 Mutation, and TET2 Nonsense are the most common alterations in aggressive non-hodgkin lymphoma .
There are 3 clinical trials for aggressive non-hodgkin lymphoma, of which 3 are open and 0 are completed or closed. Of the trials that contain aggressive non-hodgkin lymphoma as an inclusion criterion, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).
Azd5153, car.cd30-expressing autologous epstein-barr virus-specific cytotoxic t-lymphocytes, and hu5f9-g4 are the most common interventions in aggressive non-hodgkin lymphoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.